Opus Genetics, Inc. (NASDAQ:IRD), a pharmaceutical preparations company with a market capitalization of $36.3 million, has updated its executive employment agreements, enhancing severance terms for its top executives, according to a recent SEC filing.
This modification, effective January 17, 2025, specifically impacts Dr. George Magrath, CEO, and Nirav Jhaveri, CFO, of the Durham, NC-based company. According to InvestingPro analysis, the company maintains a FAIR financial health score of 2.41 out of 5.
The amendments, referred to as the Magrath Amendment and Restatement and the Jhaveri Amendment, respectively, adjust the severance payments the executives are entitled to in the event of a termination connected with a change in control. Dr. Magrath's severance multiple is set at 1.5 times the sum of his annual base salary and target bonus, while Mr. Jhaveri's is at 1.0 times that sum. Notably, InvestingPro data shows the company maintains a strong liquidity position, with current assets exceeding short-term obligations by a ratio of 6.63.
Additionally, both executives are now eligible for continued COBRA coverage following a qualifying termination, with Dr. Magrath receiving up to 18 months and Mr. Jhaveri up to 12 months. The Magrath Amendment and Restatement also includes a provision for a prorated target annual bonus for the year of termination if Dr. Magrath's employment ends prior to a change in control.
Furthermore, the Jhaveri Amendment extends the period during which a qualifying termination can lead to enhanced severance benefits to three months prior to a change in control.
Opus Genetics trades on The Nasdaq Stock Market under the ticker symbol (NASDAQ:IRD). InvestingPro analysis indicates the stock is currently trading below its Fair Value, with analysts setting price targets ranging from $8 to $15. Subscribers can access 8 additional ProTips and comprehensive financial metrics to better evaluate the company's investment potential.
In other recent news, Opus Genetics, a pharmaceutical company, has been making significant strides in its operations. Opus Genetics has established a $40 million at-the-market equity issuance program, with Leerink Partners LLC facilitating the sale of shares. The company is planning to invest the proceeds in interest-bearing, investment-grade securities, certificates of deposit, or government securities.
Opus Genetics has also reached a Special Protocol Assessment agreement with the U.S. Food and Drug Administration for a Phase 3 clinical trial of APX3330, a drug developed for the treatment of non-proliferative diabetic retinopathy. This development comes after the company's merger with Ocuphire Pharma, forming a new entity focused on inherited retinal diseases.
H.C. Wainwright has assigned a Buy rating to Opus Genetics, citing the potential of the company's inherited retinal disease platform and the 2025 catalysts for ongoing innovation. Despite negative earnings per share of $1.09, these recent developments underscore Opus Genetics' commitment to advancing treatments for eye conditions.
Opus Genetics has also set April 30, 2025, for its Annual Meeting of Stockholders. The company maintains a strong liquidity position with a current ratio of 6.63, indicating solid short-term financial stability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.